Literature DB >> 21327445

Use of daptomycin in complicated cases of infective endocarditis.

I Das1, T Saluja, R Steeds.   

Abstract

Infective endocarditis (IE) is a serious form of infection with a high mortality. Medical management can be a challenge because of organ dysfunction, lack of clinical response or allergy to the recommended antibiotics. Daptomycin is a lipopeptide antibiotic with a potent bactericidal activity against Gram-positive bacteria. There are limited data on the use of daptomycin in complicated cases of IE. We aim to report our experience of daptomycin use in complicated cases of IE through a prospective observational study (from 1 October 2008 to 30 September 2009). Daptomycin was prescribed for cases that were either unresponsive or allergic to the standard therapy. Clinical characteristics and outcomes were reviewed. Success was defined as clinical improvement accompanied with the resolution of laboratory markers of sepsis and continuation of the above findings for at least 8 weeks after the end of therapy. Eight cases were evaluable. Native and prosthetic valves were involved in equal proportions. The range of organisms was wide: Staphylococcus aureus, two cases; S. epidermidis, two cases; streptococci, two cases; and Enterococcus faecalis, two cases. The median duration of therapy was 42 days. All patients were successfully treated. Daptomycin was well tolerated. Daptomycin is useful in the management of complicated cases of IE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327445     DOI: 10.1007/s10096-011-1160-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Authors:  J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey
Journal:  Clin Infect Dis       Date:  2000-04-03       Impact factor: 9.079

2.  Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.

Authors:  Kerry L LaPlante; Suzanne Woodmansee
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

3.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Authors:  Vance G Fowler; Helen W Boucher; G Ralph Corey; Elias Abrutyn; Adolf W Karchmer; Mark E Rupp; Donald P Levine; Henry F Chambers; Francis P Tally; Gloria A Vigliani; Christopher H Cabell; Arthur Stanley Link; Ignace DeMeyer; Scott G Filler; Marcus Zervos; Paul Cook; Jeffrey Parsonnet; Jack M Bernstein; Connie Savor Price; Graeme N Forrest; Gerd Fätkenheuer; Marcelo Gareca; Susan J Rehm; Hans Reinhardt Brodt; Alan Tice; Sara E Cosgrove
Journal:  N Engl J Med       Date:  2006-08-17       Impact factor: 91.245

4.  Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Ann F Bolger; Matthew E Levison; Patricia Ferrieri; Michael A Gerber; Lloyd Y Tani; Michael H Gewitz; David C Tong; James M Steckelberg; Robert S Baltimore; Stanford T Shulman; Jane C Burns; Donald A Falace; Jane W Newburger; Thomas J Pallasch; Masato Takahashi; Kathryn A Taubert
Journal:  Circulation       Date:  2005-06-14       Impact factor: 29.690

5.  Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin.

Authors:  George Sakoulas; Jeff Alder; Claudie Thauvin-Eliopoulos; Robert C Moellering; George M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

6.  Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study.

Authors:  David R Murdoch; G Ralph Corey; Bruno Hoen; José M Miró; Vance G Fowler; Arnold S Bayer; Adolf W Karchmer; Lars Olaison; Paul A Pappas; Philippe Moreillon; Stephen T Chambers; Vivian H Chu; Vicenç Falcó; David J Holland; Philip Jones; John L Klein; Nigel J Raymond; Kerry M Read; Marie Francoise Tripodi; Riccardo Utili; Andrew Wang; Christopher W Woods; Christopher H Cabell
Journal:  Arch Intern Med       Date:  2009-03-09

7.  Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.

Authors:  Satish K Pillai; Christine Wennersten; Lata Venkataraman; George M Eliopoulos; Robert C Moellering; Adolf W Karchmer
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

8.  Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer.

Authors:  Gilbert Habib; Bruno Hoen; Pilar Tornos; Franck Thuny; Bernard Prendergast; Isidre Vilacosta; Philippe Moreillon; Manuel de Jesus Antunes; Ulf Thilen; John Lekakis; Maria Lengyel; Ludwig Müller; Christoph K Naber; Petros Nihoyannopoulos; Anton Moritz; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

9.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy.

Authors:  T S J Elliott; J Foweraker; F K Gould; J D Perry; J A T Sandoe
Journal:  J Antimicrob Chemother       Date:  2004-11-16       Impact factor: 5.790

View more
  6 in total

1.  Effectiveness and safety of daptomycin in patients with infective endocarditis undergoing heart valve replacement: a subgroup analysis from real-world data.

Authors:  Achyut Guleri; Riccardo Utili; Pascal Dohmen; Kamal Hamed
Journal:  Ther Adv Infect Dis       Date:  2017-02-17

2.  Management of MRSA/GISA, VISA Endocarditis.

Authors:  Cédric Jacqueline; Jocelyne Caillon; David Boutoille
Journal:  Curr Infect Dis Rep       Date:  2013-08       Impact factor: 3.725

3.  High-dose daptomycin therapy for left-sided infective endocarditis: a prospective study from the international collaboration on endocarditis.

Authors:  Manuela Carugati; Arnold S Bayer; Josè M Miró; Lawrence P Park; Armenio C Guimarães; Athanasios Skoutelis; Claudio Q Fortes; Emanuele Durante-Mangoni; Margaret M Hannan; Francisco Nacinovich; Nuria Fernández-Hidalgo; Paolo Grossi; Ru-San Tan; Thomas Holland; Vance G Fowler; Ralph G Corey; Vivian H Chu
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

4.  A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms.

Authors:  Julia Bauer; Wafi Siala; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

5.  Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin(®) Outcomes Registry and Experience (EU-CORE).

Authors:  Achyut Guleri; Riccardo Utili; Pascal Dohmen; Nicola Petrosillo; Cornelia Piper; Rashidkhan Pathan; Kamal Hamed
Journal:  Infect Dis Ther       Date:  2015-07-14

6.  Epidemiology and prognosis of coagulase-negative staphylococcal endocarditis: impact of vancomycin minimum inhibitory concentration.

Authors:  Cristina García de la Mària; Carlos Cervera; Juan M Pericàs; Ximena Castañeda; Yolanda Armero; Dolors Soy; Manel Almela; Salvador Ninot; Carlos Falces; Carlos A Mestres; Jose M Gatell; Asuncion Moreno; Francesc Marco; José M Miró
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.